Search research articles
Contact Us
Filters
Showing results (21-30 of 41) with videos related to
Page
of 5
Sort By:
Nature Medicine
|
January 4, 2024
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, et al.
Blood Cancer Journal
|
September 11, 2024
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
Arleigh McCurdy, Donna Reece, Martha L Louzada, et al.
Clinical Colorectal Cancer
|
January 25, 2016
Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients
Julia Sun, Alastair I Ilich, Christina A Kim, et al.
Blood Cancer Journal
|
February 3, 2023
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics
Daisuke Ogiya, Zuzana Chyra, Sigitas J Verselis, et al.
Quantitative Imaging in Medicine and Surgery
|
June 7, 2024
Automated detection and classification of coronary atherosclerotic plaques on coronary CT angiography using deep learning algorithm
Jing Liang, Kefeng Zhou, Michael P Chu, et al.
Immunology and Cell Biology
|
March 18, 2017
MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells
Ratna Sanyal, Maria J Polyak, Jonathan Zuccolo, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 28, 2025
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis
Arleigh McCurdy, Engin Gul, Donna Reece, et al.
Blood Neoplasia
|
May 25, 2026
Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report
Martha L Louzada, Donna Reece, Christopher P Venner, et al.
Transplantation and Cellular Therapy
|
July 6, 2024
Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database
Christopher P Venner, Peter Duggan, Kevin Song, et al.
Nature Medicine
|
October 2, 2023
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 41) with videos related to
Sort By:
Page
of 5
Nature Medicine
|
January 4, 2024
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, et al.
Blood Cancer Journal
|
September 11, 2024
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
Arleigh McCurdy, Donna Reece, Martha L Louzada, et al.
Clinical Colorectal Cancer
|
January 25, 2016
Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients
Julia Sun, Alastair I Ilich, Christina A Kim, et al.
Blood Cancer Journal
|
February 3, 2023
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics
Daisuke Ogiya, Zuzana Chyra, Sigitas J Verselis, et al.
Quantitative Imaging in Medicine and Surgery
|
June 7, 2024
Automated detection and classification of coronary atherosclerotic plaques on coronary CT angiography using deep learning algorithm
Jing Liang, Kefeng Zhou, Michael P Chu, et al.
Immunology and Cell Biology
|
March 18, 2017
MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells
Ratna Sanyal, Maria J Polyak, Jonathan Zuccolo, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 28, 2025
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis
Arleigh McCurdy, Engin Gul, Donna Reece, et al.
Blood Neoplasia
|
May 25, 2026
Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report
Martha L Louzada, Donna Reece, Christopher P Venner, et al.
Transplantation and Cellular Therapy
|
July 6, 2024
Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database
Christopher P Venner, Peter Duggan, Kevin Song, et al.
Nature Medicine
|
October 2, 2023
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, et al.
Page
of 5